Clinical Trials Directory

Trials / Completed

CompletedNCT03477734

Performance and Efficacy of the CardiacSense1 for Detection of Atrial Fibrillation

A Prospective, Open, Multi-Center, Controlled Study to Evaluate the Safety, Performance and Efficacy of the CardiacSense1 for Detection of Atrial Fibrillation

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
53 (actual)
Sponsor
CardiacSense Ltd. · Industry
Sex
All
Age
18 Years – 85 Years
Healthy volunteers
Accepted

Summary

A Prospective, Open, Multi-Center, Controlled Study to Evaluate the Safety, Performance and Efficacy of the CardiacSense1 for Detection of Atrial Fibrillation. The clinical study is intended to establish the efficacy and safety of the CardiacSense1 wearable device intended to monitor and detect heart arrhythmia, specifically atrial fibrillation (A-Fib) based on a comparison to a control device, which is an off-the-shelf cleared Holter ECG device

Detailed description

The clinical study is intended to establish the efficacy and safety of the CardiacSense1 wearable device intended to monitor and detect heart arrhythmia, specifically atrial fibrillation (A-Fib). Study design as as follows: 100 subjects, 50 (at least 30% of each gender) with A-fib and 50 without (at least 30% of each gender). All subjects will be measured during at least 24 hours. Primary endpoint - A-Fib detection Control: Holter device will be the reference For PPG analysis, each one hour will be considered as an event: If A-Fib is present for more than accumulated 5 minutes in that specific hour then it shall be considered an "A-Fib hour" If A-fib was present for less than accumulated 5 minutes then it shall be considered a "Non-A-Fib hour". For ECG analysis, each measurement of between 1-3 minutes will be considered an event. If A-Fib is present at that specific measurement, then it shall be considered an "A-Fib event" If A-fib was not present at that specific measurement, then it shall be considered a "Non-A-Fib hour". Sensitivity (true positive) is defined as the percentage of Holter defined "A-fib hours"/"A-Fib event" found by PPG/ECG. The asked sensitivity is 90%. Specificity (true negative) is defined as the percentage of Holter defined "Non-A-fib hours"/"A-Fib event" found by PPG/ECG. The required specificity is 90%.

Conditions

Interventions

TypeNameDescription
DEVICECS1 & heart monitorDaily activities while wearing the investigational device as well as the control device

Timeline

Start date
2019-02-20
Primary completion
2019-11-25
Completion
2020-06-09
First posted
2018-03-26
Last updated
2020-07-21

Locations

2 sites across 1 country: Israel

Source: ClinicalTrials.gov record NCT03477734. Inclusion in this directory is not an endorsement.